RxDoctor Payments Data

Matthew Schrettner, MD

Neurology · Greer, SCNPI 1972845766

Payments from drug & device makers

$1,545in general payments, 2019–2025

Across 84 payments — averaging $18.39 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Livanova USA, Inc.$372
  • UCB, Inc.$198
  • Sanofi$154
  • Amgen$146
  • Acadia Pharmaceuticals Inc$97
  • Eisai Inc.$86
  • plus $492 from 16 others

What the payments were for

  • Speaking & faculty fees$594%
  • Food & beverage$1,48696%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,545 in reported general payments places this provider in the 55th percentile of 270 neurology providers in South Carolina.

See all neurology providers in South Carolina

Medicare billing

Part B allowed, 2024
$67,507
Medicare patients
390
Services billed
510

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
AptiomEslicarbazepine Acetate43$103,240
BriviactBrivaracetam60$96,706
EpidiolexCannabidiol (Cbd)22$94,504
MysolinePrimidone11$58,696
OnfiClobazam12$36,255
Aimovig AutoinjectorErenumab-Aooe41$29,678
FycompaPerampanel12$20,785
Nurtec OdtRimegepant Sulfate21$20,509
Levetiracetam316$19,352
Lacosamide178$18,754
Oxcarbazepine64$11,620
NayzilamMidazolam17$11,571
Ajovy AutoinjectorFremanezumab-Vfrm15$10,610
Lamotrigine ErLamotrigine20$8,839
Levetiracetam ErLevetiracetam39$5,644

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
UCB, Inc.Briviact, Nayzilam$198$108,27777 claims
Lundbeck LLCOnfi$19$36,25512 claims
Eisai Inc.Fycompa$86$20,78512 claims
Upsher-smith Laboratories LLCTopiramate$22$1,46763 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 270 neurology providers in South Carolina.

Other neurology in Greer

See the full list for South Carolina

Where these figures come from

Is this you, or does something look wrong? →